Trial results show high remission rate in leukemia following immune cell therap

Children and young adults with chemotherapy-resistant B-cell acute lymphoblastic leukemia (ALL) experienced high remission rates following treatment with an experimental immunotherapy. This finding, from an early-phase clinical trial, is important because children and young adults with chemotherapy-resistant leukemia who do not achieve remission have very poor outcomes. Results from this ongoing clinical trial, headed by Crystal L. Mackall, M.D., chief of the Pediatric Oncology Branch in NCI’s Center for Cancer Research, demonstrated that the immunotherapy treatment had anti-leukemia effects in patients and that the treatment was feasible and safe. Read more here.